January 27, 2027 | NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth; Cytespace expanded its molecular testing to meet increasing demands across Sub-Saharan Africa; Daisy Genomics and New Day Diagnostics have entered a collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance; and more.
Cytespace expanded its molecular testing capabilities to meet rising demand across Sub-Saharan Africa. With the installation of multiple Roche cobas 5800 systems, Cytespace has tripled its molecular diagnostic throughput, enabling high-volume, fully automated PCR testing to support a growing portfolio of clinical trials in infectious disease and beyond. This strategic expansion enhances the laboratory's capacity to support sponsors running vaccine and therapeutic trials for high-burden diseases such as HIV, Hepatitis B and C, sexually transmitted infections, and emerging respiratory or transplant-related infections. Press release.
Researchers from Helmholtz Munich and the Technical University of Munich have developed fast-RSOM, a new imaging technology that can capture detailed images of the smallest blood vessels directly through the skin without the need for invasive procedures. By revealing early signs of cardiovascular risk, this technology could help doctors intervene sooner, guide personalized therapies, and improve long-term heart health. Press release.
HORIBA has obtained CE IVDR certification for its new Yumizen H500 CRP benchtop hematology analyzer which delivers a simultaneous 5-part extended differential and rapid C-Reactive Protein whole blood measurement. The new instrument is designed for small laboratories and ideal for use in a variety of hospital testing settings for rapid and highly accurate detection of infection and inflammation. Press release.
NeuroQure has launched ASD Insight, a first-of-its-kind test designed to identify autism risk as early as birth. ASD Insight provides clinicians and families with early insight into autism risk, enabling earlier, targeted interventions during the most critical stages of neurodevelopment. Studies show that children who begin autism treatment by age two experience significant cognitive and social improvements. In contrast, delayed diagnosis and intervention can lead to increased dependency and higher lifetime medical costs. Press release.
Researchers at the Wellcome Sanger Institute, Open Targets, Netherlands Cancer Institute, and their collaborators used CRISPR in a novel approach that cultured tumor cells together with immune cells from the same individual to measure immune killing of cancer cells. This enabled them to identify which genes make tumors cells more or less vulnerable to immune attack. The study provides insight on why some patients are more or less likely to respond to certain types of cancer treatments and could guide the development of more successful personalized treatments. Press release.
Researchers from the Institute of Science, Tokyo developed DiaCardia, an AI model that detects prediabetes using electrocardiogram (ECG) data alone, without relying on blood tests. During internal testing, DiaCardia achieved an area under the receiver operating characteristic curve of 0.851 using ECG data alone. The model also performed well when evaluated on external data from another institution, without retraining, indicating strong generalizability. Press release.
Elekta’s Elekta Evo CT-Linac has received 510(k) clearance from the U.S. Food and Drug Administration (FDA). This milestone makes the system available to radiation oncology professionals in the United States. When delivering radiation therapy, clinicians require high-quality images that allow them to identify tumors and organs at risk. Evo addresses this with Iris high-definition, AI-enhanced imaging, which allows physicians to see target areas and critical structures for every fraction with greater clarity. In Europe and other countries, Elekta Evo continues to gain traction as more clinics adopt it for treatment capabilities. Press release.
Daisy Genomics and New Day Diagnostics have announced a strategic research collaboration with the University of Tennessee and the East Tennessee Health Innovation Alliance to develop next-generation epigenetic sequencing and liquid biopsy tools for early colorectal cancer detection. The partnership will integrate New Day’s clinically validated CRC liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform. The companies aim to generate data demonstrating how direct detection of epigenetic signals—without chemical amplification or traditional sequencing bottlenecks—can enable earlier, more accurate, and more scalable cancer screening. Research will be conducted across New Day’s CLIA-certified laboratory and the University of Tennessee. The collaboration may also leverage capabilities within the University of Tennessee’s Institute for Advanced Materials & Manufacturing, whose nanoscale engineering, microfabrication resources, and materials science expertise align with Daisy Genomics’ chip design and manufacturing roadmap. Press release.